Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Therapeutic Potential of Apremilast as Add-on Therapy to Second-Generation H1 Antihistamines in the Management of Chronic Urticaria: A Non-Randomised Controlled Trial

NCT07850843 is registered in ClinicalTrials.gov with Rashid Latif Medical College as lead sponsor.

NCT NCT07850843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07850843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Therapeutic Potential of Apremilast as Add-on Therapy to Second-Generation H1 Antihistamines in the Management of Chronic Urticaria: A Non-Randomised Controlled Trial
Lead sponsor
Rashid Latif Medical College
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
September 23, 2026
Completion date
October 31, 2026
Enrollment
86 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic inducible urticaria, chronic spontaneous urticaria, chronic urticaria